Balanced news tone
News Sentiment
SVRA sentiment intelligence
Savara Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
82/100 classification confidence.
directly relevant articles
high-authority source matches
-8.5% over one week, +0.4% over four weeks, trend inactive, and materially above fair value.
Join Class Action to Recover Losses from Savara Inc. (SVRA) - Contact Levi & Korsinsky Before November 7, 2025
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Savara Inc (SVRA), focusing on its support and resistance levels, various technical indicators, and moving averages. As of June 16, 2026, SVRA has a price momentum score of 8.99 and is trading between a resistance level of 5.65 and a
- Tone
- Positive 60/100
- Event
- Market update
- Published
- 17 Jun 2026 02:10
- Source
- TradingKey
Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Savara Inc (SVRA), assigning it a weak financial score of 5.22 out of 388 in the Biotechnology & Medical Research industry, indicating low operating efficiency. Key financial metrics such as cash and cash equivalents, total assets, to
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 17 Jun 2026 02:10
- Source
- TradingKey
Savara (SVRA) Proxy filing Summary
Savara (SVRA) has scheduled its annual meeting for June 4, 2026, where shareholders will vote on board elections, an increase in authorized common stock, amendments to incentive plans, auditor ratification, and executive compensation. The company is preparing for the potential co
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 16 Jun 2026 14:10
- Source
- Quartr
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Savara Inc (SVRA) has an earnings forecast score of 8.75, ranking high within its industry. Analysts have set an average price target of $10.25, with a consensus "Buy" rating based on 8 analysts. The company's previous quarter's EPS outperformed market expectations, and the next
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jun 2026 12:39
- Source
- TradingKey
Savara Announces New Employment Inducement Grant
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 20:05
- Source
- Business Wire
Savara gives new hires stock tied to revenue milestone target
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 Jun 2026 07:00
- Source
- Stock Titan
Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Market source
Savara (SVRA) expands share capacity and appoints Robert Lutz as CFO/COO
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Stock Titan
Savara Announces Chief Financial and Administrative Officer Transition
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Business Wire
Health-related exit at Savara: COO Robert Lutz takes finance role
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Stock Titan
Savara: The Rare Disease Funnel Is Becoming A Commercial Asset (NASDAQ:SVRA)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- Seeking Alpha
Savara Inc. (SVRA) Reports Q1 Financial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 22 May 2026 18:43
- Source
- Insider Monkey
Rare lung disease trial: Savara drug cuts biomarkers tied to severity
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 20 May 2026 07:00
- Source
- Stock Titan
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Savara Q1 Loss Widens
- Tone
- Negative 42/100
- Event
- Market update
- Published
- 12 May 2026 20:33
- Source
- MT Newswires
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Apr 2026 07:00
- Source
- Market source
Savara’s FDA Review Extension Keeps Molgramostim Thesis Intact But Delayed
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Apr 2026 07:00
- Source
- simplywall.st
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Savara gives 24 new hires stock awards tied to tenure and revenue
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Apr 2026 07:00
- Source
- Stock Titan
FDA Extends Review of Savara’s Molgramostim BLA for PAP
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Apr 2026 07:00
- Source
- BioPharm International
Savara's rare lung disease drug gets 3 more months at FDA
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Apr 2026 07:00
- Source
- Stock Titan
Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Mar 2026 08:00
- Source
- Market source
Savara Stock: A High-Risk Opportunity (NASDAQ:SVRA)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Nov 2025 08:00
- Source
- Seeking Alpha
Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Oct 2025 07:00
- Source
- Business Wire
Savara (SVRA) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Apr 2025 23:55
- Source
- Stock Titan
Savara Begins Rolling BLA for Molbreevi for Rare Lung Disease
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Dec 2024 08:00
- Source
- Managed Healthcare Executive